摘要
抗3-羟基3-甲基戊二酰辅酶A还原酶(HMGCR)抗体介导的坏死性肌病是近年逐渐被认识的一类疾病,该病与他汀类药物的使用密切相关。患者具有坏死性肌病的一般特点,通过抗HMGCR抗体阳性与其他类型的坏死性肌病相鉴别。多数患者可通过激素联合其他免疫抑制剂治疗可控制病情。文中回顾了该病的发病机制、流行病学、临床特点、诊断及鉴别诊断、治疗等研究现状,以加强临床医生对该病的认识。
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase （HMGCR） antibody mediated necrotizing myopathy is gradually known by clinical doctors in recent years. Its incidence is low. Statins may be a triggering factor of this disease. Patients have the general characters of necrotizing myopathy, and can be distinguished from other kinds of necrotizing myopathy by anti-HMGCR antibody positive. Glucocorticoids are the most common initial immunosuppressive agent, but other kinds of immunosuppressants are often necessary. The etiology, epidemiology, clinical characteristics, diagnosis and treatment of anti-HMGCR antibody-mediated autoimmune necrotizing myopathy were reviewed.
出处
《中国临床神经科学》
2017年第2期191-197,共7页
Chinese Journal of Clinical Neurosciences
